Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 888

1.

Involvement of the kynurenine pathway in human glioma pathophysiology.

Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, Sundaram G, Braidy N, Brew BJ, Guillemin GJ.

PLoS One. 2014 Nov 21;9(11):e112945. doi: 10.1371/journal.pone.0112945. eCollection 2014.

2.

The kynurenine pathway in brain tumor pathogenesis.

Adams S, Braidy N, Bessede A, Brew BJ, Grant R, Teo C, Guillemin GJ.

Cancer Res. 2012 Nov 15;72(22):5649-57. doi: 10.1158/0008-5472.CAN-12-0549. Epub 2012 Nov 9. Review. Erratum in: Cancer Res. 2012 Dec 15;72(24):6524. Bessesde, Alban [corrected to Bessede, Alban].

4.

Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.

Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Grant R.

FEBS J. 2011 Nov;278(22):4425-34. doi: 10.1111/j.1742-4658.2011.08366.x.

5.

Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.

Yan EB, Frugier T, Lim CK, Heng B, Sundaram G, Tan M, Rosenfeld JV, Walker DW, Guillemin GJ, Morganti-Kossmann MC.

J Neuroinflammation. 2015 May 30;12:110. doi: 10.1186/s12974-015-0328-2.

6.

The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.

Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, Grant R, Brew BJ, Guillemin GJ.

Neurotox Res. 2010 Aug;18(2):132-42. doi: 10.1007/s12640-009-9129-7. Epub 2009 Nov 18.

PMID:
19921535
7.

Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.

Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C, Reinke P.

Nephrol Dial Transplant. 2009 Jun;24(6):1901-8. doi: 10.1093/ndt/gfn739. Epub 2009 Jan 20.

PMID:
19155537
8.

Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.

Wu W, Nicolazzo JA, Wen L, Chung R, Stankovic R, Bao SS, Lim CK, Brew BJ, Cullen KM, Guillemin GJ.

PLoS One. 2013 Apr 22;8(4):e59749. doi: 10.1371/journal.pone.0059749. Print 2013.

9.
10.

Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.

Myint AM, Kim YK.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13. doi: 10.1016/j.pnpbp.2013.08.008. Epub 2013 Oct 31. Review.

PMID:
24184687
11.

Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.

Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):345-52. doi: 10.1007/s00406-012-0384-x. Epub 2012 Nov 29.

PMID:
23192697
12.

Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis.

Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ, Brew BJ.

Redox Rep. 2000;5(2-3):108-11.

PMID:
10939285
13.

Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria.

Sanni LA, Thomas SR, Tattam BN, Moore DE, Chaudhri G, Stocker R, Hunt NH.

Am J Pathol. 1998 Feb;152(2):611-9.

14.

Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.

Song P, Ramprasath T, Wang H, Zou MH.

Cell Mol Life Sci. 2017 Aug;74(16):2899-2916. doi: 10.1007/s00018-017-2504-2. Epub 2017 Mar 17. Review.

15.

Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.

Mazarei G, Budac DP, Lu G, Adomat H, Tomlinson Guns ES, Möller T, Leavitt BR.

J Neurochem. 2013 Dec;127(6):852-67. doi: 10.1111/jnc.12350. Epub 2013 Jul 15.

16.

Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.

Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T, Akiyama Y, Tsuchiya M.

J Neurosurg. 2009 Aug;111(2):230-7. doi: 10.3171/2008.10.JNS081141.

PMID:
19199463
17.

L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.

Fujigaki H, Yamamoto Y, Saito K.

Neuropharmacology. 2017 Jan;112(Pt B):264-274. doi: 10.1016/j.neuropharm.2016.01.011. Epub 2016 Jan 6. Review.

PMID:
26767951
18.

Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.

Doolin K, Allers KA, Pleiner S, Liesener A, Farrell C, Tozzi L, O'Hanlon E, Roddy D, Frodl T, Harkin A, O'Keane V.

Psychoneuroendocrinology. 2018 Sep;95:8-17. doi: 10.1016/j.psyneuen.2018.05.019. Epub 2018 May 19.

PMID:
29787958
19.

The niacin required for optimum growth can be synthesized from L-tryptophan in growing mice lacking tryptophan-2,3-dioxygenase.

Terakata M, Fukuwatari T, Kadota E, Sano M, Kanai M, Nakamura T, Funakoshi H, Shibata K.

J Nutr. 2013 Jul;143(7):1046-51. doi: 10.3945/jn.113.176875. Epub 2013 May 22.

PMID:
23700344
20.

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.

Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M.

Mol Psychiatry. 2005 Jun;10(6):538-44.

PMID:
15494706

Supplemental Content

Support Center